ProtoKinetix, Inc. (OTCMKTS:PKTX) CEO Clarence Edward Smith purchased 252,030 shares of the company’s stock in a transaction that occurred on Monday, April 29th. The shares were purchased at an average cost of $0.12 per share, for a total transaction of $30,243.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Clarence Edward Smith also recently made the following trade(s):
- On Tuesday, June 4th, Clarence Edward Smith purchased 142,252 shares of ProtoKinetix stock. The shares were purchased at an average cost of $0.15 per share, for a total transaction of $21,337.80.
PKTX stock opened at $0.20 on Thursday. ProtoKinetix, Inc. has a 12-month low of $0.05 and a 12-month high of $0.32. The stock’s 50 day simple moving average is $0.23 and its 200 day simple moving average is $0.14.
ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company's AFGPs have commercial applications primarily in food and crop preservation at freezing temperatures.
Recommended Story: Mutual funds are not immune from market timing
Receive News & Ratings for ProtoKinetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProtoKinetix and related companies with MarketBeat.com's FREE daily email newsletter.